Please login to the form below

Not currently logged in
Email:
Password:

Pfizer scraps RA drug

Pfizer has decided to scrap development of TRU-015 for the treatment of rheumatoid arthritis

Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). Seattle-based Trubion Pharmaceuticals, which has a collaboration in RA with the company, said that Pfizer has terminated development of TRU-015, a protein therapeutic product.

The decision is based on a phase IIb study which did not meet its primary endpoint of a 20 per cent reduction on an American College of Rheumatology disease scoring index compared to placebo.

Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087. That drug is currently in a phase II study.

15th June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics